As of Aug 8, 2025, the NBIX stock has a PE ratio of 35.92. The calculation is based on the latest EPS of $3.48 and the stock price of $125.01 per share. The PE ratio currently is comparable to its last four-quarter average.
The mean historical PE ratio of Neurocrine Biosciences over the last seven years is 172.19. The current 35.92 P/E ratio is 79% lower than the historical average. Looking back at the last seven years, NBIX's PE ratio peaked in the Sep 2018 quarter at 1,229.5, with a price of $122.95 and an EPS of $0.1. The Sep 2021 quarter marked the lowest point at 20.11, with a price of $95.91 and an EPS of $4.77.
Maximum annual increase: 648% in 2012
Maximum annual decrease: -91.86% in 2020
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | 40.15 | -21.99% | $136.5 | $3.4 |
2023 | 51.47 | -30.62% | $131.76 | $2.56 |
2022 | 74.19 | -17.24% | $119.44 | $1.61 |
2021 | 89.65 | 309.73% | $85.17 | $0.95 |
2020 | 21.88 | -91.86% | $95.85 | $4.38 |
2019 | 268.73 | -13.45% | $107.49 | $0.4 |
2018 | 310.48 | N/A | $71.41 | $0.23 |
2017 | N/A | N/A | $77.59 | -$1.62 |
2016 | N/A | N/A | $38.7 | -$1.63 |
2015 | N/A | N/A | $56.57 | -$1.05 |
2014 | N/A | N/A | $22.34 | -$0.81 |
2013 | N/A | N/A | $9.34 | -$0.69 |
2012 | 93.5 | 648% | $7.48 | $0.08 |
2011 | 12.5 | N/A | $8.5 | $0.68 |
2010 | N/A | N/A | $7.64 | -$0.15 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Jun 2025 | 36.12 | -1.04% | $125.69 | $3.48 |
Mar 2025 | 36.5 | -9.09% | $110.6 | $3.03 |
Dec 2024 | 40.15 | 34.51% | $136.5 | $3.4 |
Sep 2024 | 29.85 | -25.64% | $115.22 | $3.86 |
Jun 2024 | 40.14 | 9.73% | $137.67 | $3.43 |
Mar 2024 | 36.58 | -28.93% | $137.92 | $3.77 |
Dec 2023 | 51.47 | -10.33% | $131.76 | $2.56 |
Sep 2023 | 57.4 | 11.39% | $112.5 | $1.96 |
Jun 2023 | 51.53 | -65.89% | $94.3 | $1.83 |
Mar 2023 | 151.07 | 103.63% | $101.22 | $0.67 |
Dec 2022 | 74.19 | -57.39% | $119.44 | $1.61 |
Sep 2022 | 174.11 | -76.78% | $106.21 | $0.61 |
Jun 2022 | 749.85 | 507.86% | $97.48 | $0.13 |
Mar 2022 | 123.36 | 37.6% | $93.75 | $0.76 |
Dec 2021 | 89.65 | 345.8% | $85.17 | $0.95 |
NBIX's current PE ratio is lower than its 3, 5 and 10-year averages.
In comparison to its peers LLY and ABBV, NBIX's PE ratio is lower, but it is higher than PFE's and RPRX's.
Stock name | PE ratio | Market cap |
---|---|---|
PFE Pfizer Inc | 13.01 | $139.75B |
RPRX Royalty Pharma plc | 16.27 | $21.92B |
NBIX Neurocrine Biosciences Inc | 35.92 | $12.4B |
LLY ELI LILLY & Co | 40.76 | $592.15B |
ABBV AbbVie Inc | 93.86 | $349.87B |
RGEN Repligen Corp | N/A | $6.27B |
ANIP Ani Pharmaceuticals Inc | N/A | $1.77B |
CASI CASI Pharmaceuticals Inc | N/A | $25.25M |
The price to earnings ratio for NBIX stock is 35.92 as of Aug 8, 2025.
Over the last 3 years, the average price to earnings ratio for NBIX stock is 64.93.
Over the last 5 years, the average price to earnings ratio for NBIX stock is 96.33.
The highest quarterly PE ratio in the last seven years has been 1,229.5 and it was in the Sep 2018 quarter.
NBIX's current price to earnings ratio is 79% below its 7-year historical average.
The P/E ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (Aug 8, 2025), Neurocrine Biosciences's share price is $125.01. The company's earnings per share for the trailing twelve months (TTM) ending Jun 2025 is $3.48. Therefore, Neurocrine Biosciences's PE ratio for today is 35.92. PE RATIO(35.92) = STOCK PRICE($125.01) / TTM EPS($3.48)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.